The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi […]readmore
Tags : NextCure
Shots: NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs The […]readmore